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S U M M A R Y
Persistent infection with human papillomavirus (HPV) causes essentially all precancerous cervical
lesions and cervical cancer in females and thus is an important intermediate phenotype to cervical
cancer. A majority of infected individuals naturally clear HPV viral infection, but the virus persists in a
subset of infected hosts and the mechanism for this differential outcome is not well described. Most of
the epidemiological studies have been cross-sectional in nature, and even with longitudinal studies, the
deﬁnition of HPV persistence or clearance has not been well deﬁned. There is no consensus on the correct
time interval between HPV DNA tests, or how to utilize HPV persistence information in clinical
management because there is no treatment for HPV. While most studies are performed with the
endpoint of cancer, the intermediate phenotype has been overlooked. Epidemiological studies of HPV
persistence suffer with several challenges in deﬁnitions, study designs, and analyses that undermine its
importance in identifying and understanding the interactions between the viral and host genomes in the
process of HPV infection pathogenesis. We have evaluated the current status of HPV persistence and
provide perspectives on how the ﬁeld would beneﬁt from a research focus on intermediate phenotype in
epidemiological studies.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Human papillomavirus (HPV) is one of the most common
causes of sexually transmitted infections (STIs) in both men and
women. The virus is highly contagious and studies have estimated
HPV transmission probability to be as high as 40–60% following
unprotected sexual intercourse.1 Annually, 160 million incident
infections of HPV are estimated worldwide; however, as you
progress to dysplasia and then to cervical cancer (529 409) the
rates signiﬁcantly decrease2–4 (Figure 1). Incident HPV infections
seem to be age-dependent, where HPV infections peak soon after
the age when most young women become sexually active (average
age of 20 years), and this is usually followed by a gradual decline.
Approximately 80% of the female population is exposed to HPV
sometime in their lifetime, but the infection is usually transient,
with 70–90% of infected individuals ‘clearing’ the virus (HPV DNA
undetectable by assays) within 12–24 months, and only a small
proportion will progress to cervical cancer (Figure 1).5,6 The main
consequence of persistent infection with HPV is the development
of precancerous cervical lesions that may progress to malignancy* Corresponding author. Tel.: +1 205 934 6459; fax: +1 205 934 8665.
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http://dx.doi.org/10.1016/j.ijid.2012.12.027in the next 5–15 years after infection, and this subsequently could
result in invasive cervical cancer.7
HPV persistence has been consistently and strongly associated
with precancerous lesions.8,9 A recent 16-year longitudinal study
also conﬁrmed the critical role of persistent carcinogenic HPV
infections in predicting the risk of cervical cancer in women.10 Based
on this study, the 16-year risk of cervical cancer was 6.2% among
women infected with any carcinogenic (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 59) HPV, and 13.5%, 10.3%, or 4.0% for women infected
with HPV16, HPV58, or other carcinogenic HPVs (without HPV 16
and 58), respectively. However, the rates were lower with other HPV
type infections: 2.1%, 1.1%, and 0.26% among women infected with
possibly/probably carcinogenic HPV types, other non-carcinogenic
HPV infections, and HPV-negative women, respectively. HPV
infections occurring at older ages could have little impact on cancer
cases compared to persistent infections occurring at an earlier age,
due to the years required for cancer development. These observa-
tions further emphasize the need for earlier detection of disease
progression by monitoring the persistent infection with HPV, before
the development of lesions. The research focus should include
persistent HPV infection since this is the known precursor of cervical
cancer. In this paper, we will focus on HPV persistence, which we
deﬁne as ‘intermediate phenotype’, and provide perspectives in
epidemiological study designs and analyses.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. HPV infection and cervical abnormalities epidemiology in the USA and worldwide.2–4
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Epidemiologic and virologic data demonstrate that 13–15 high-
risk, or oncogenic HPVs are the primary and necessary causal agents
of cervical cancer;11–13 HPV infection is attributable to 99.9% of
cervical cancers, and oncogenic HPV types 16/18 are responsible for
70% of all cervical cancers.14 Individual HPV infections are not
independent from each other in either sex, meaning that acquisition
of multiple HPV types occurs more often than expected.15However,
no two HPV types are more likely to be acquired together than any
other HPV types in several populations.15–17 While these cross-
sectional studies show strong associations, HPV is required to
persist to cause necessary cellular changes in the host to progress to
cancer. Since most HPV infections do not clear, persistent HPV
infection is a prerequisite and thus we consider it as an
‘intermediate phenotype’. An infection persisting for more than 4
years has only a small chance of remission.18 Women who have a
persistent infection can develop cervical intraepithelial neoplasia
(CIN) lesions; however a proportion of high-grade cervical lesions
may never progress to cervical cancer and can even regress without
treatment4,19,20 (Figure 2). However, the status of HPV is not known
during the cervical lesion regression process, i.e., whether regres-
sion is linked to clearance of HPV. Most epidemiological studies
have described CIN or cervical cancer as the outcome in the host and
only a few have incorporated HPV persistence as the main outcome.
HPV pathogenesis with respect to the cervical carcinogenesis in the
host should be viewed in two separate phases; ﬁrst, the biology
related to the virological and host immunological process of HPV
persistent infection; and second, the functionally important stages
in cervical cancer progression. It should be noted that the ﬁrst phase
is a prerequisite to the second phase. The limited studies on HPV
persistence suggest that multiple HPV infections,21 smoking,22 and
multiple lifetime sexual partners23,24 are the main factors
associated with persistent HPV infection. However, some of the
epidemiological and biological factors associated with cervical
cancer could be a surrogate for HPV persistence, where it is
confounded by the selection bias of HPV persistent individuals
among cancer patients. For instance, several studies have shown
human leukocyte antigens (HLA) to be associated with cervical
cancer,25 but of note, HLA and other immune-related genes may bemore involved with persistence or clearance of HPV.26 The
importance of HPV persistence as the intermediate phenotype
has been acknowledged in the clinical setting, resulting in the
inclusion of HPV testing in several screening programs. In a large
longitudinal study, Castle et al. recently described that while both
baseline Pap and HPV tests predicted the development of CIN3
within the ﬁrst 2 years of follow-up, only HPV testing predicted CIN3
in 10 to 18 years.27 Precancerous lesions and cervical cancer have
often been the public health focus and recently HPV testing has been
recommended in clinical screening.7 Similarly, persistent HPV
should also be carefully considered in research settings to
understand the dynamics of how some are susceptible to persistent
infection while most are able to overcome.28 Phenotypically, it is
extremely important for epidemiological studies to accurately
deﬁne the intermediate phenotype, determine the correct HPV
types, and systematically be able to analyze the complex data.
3. Challenges in research studies of HPV persistence, the
intermediate phenotype
3.1. Epidemiological study designs
There has been considerable heterogeneity in study design and
methodological approaches in various cohort studies examining
the natural history and persistence of HPV. The most common
epidemiological study design for HPV is a cross-sectional design
that estimates the prevalence at any time-point, but does not
provide information regarding HPV persistence and clearance.
Prevalent cases may have had the infection for a few days to years,
making these women signiﬁcantly different to those with an
incident infection during follow-up. In that sense, longitudinal
data are more powerful and are better predictors for the outcome
of interest. Ideally, a study assessing persistence of HPV in the
population needs to follow women before their ﬁrst HPV infection
and for an extended period in order to be certain that the HPV
infections are truly incident infections and not latent. Including
only those with incident HPV infections allows the researchers a
clearer understanding of when the individual was infected. While
everyday sampling is theoretically possible with self-sampling
approaches, it is logistically not quite feasible; thus, data from
Figure 2. HPV persistence and progression to cervical abnormalities timeline and estimated likelihoods of regression and progression of cervical histological lesions (data
based on various resources).4,19,20
S.L. Sudenga, S. Shrestha / International Journal of Infectious Diseases 17 (2013) e216–e220e218shorter visit periods will be more informative. There have been
very few long-term longitudinal studies that have actually
followed persistent HPV and assessed the risk of cervical cancer
among women.10,29
3.2. Deﬁnitions of HPV persistence
Correctly deﬁning the intermediate phenotype is critical for
accurate study design and analysis. ‘HPV viral persistence’ is often
deﬁned as detection of the same HPV type at two or more
intervals.8,9,30–32 In a recent meta-analysis, Rositch et al. reported
that the deﬁnition of HPV persistence was mediated by study region,
detection method, and HPV type.31 They estimated that approxi-
mately half of the HPV infections persist past 6–12 months. These
ﬁndings coincide with the current ASC/ASCCP/ASCP guidelines that
recommend a 1-year repeat screening interval for women over 30
years who are HPV-positive with normal cytology.31 If a woman is
going to clear an HPV infection, it will likely occur within a year, and
future follow-up is needed if HPV persists longer than 1 year. This
meta-analysis emphasizes the need for a concise deﬁnition of HPV
persistence and time interval between HPV DNA tests in order to
more effectively determine clinical and treatment outcomes.
After detection of the HPV virus, ‘HPV viral clearance’ is often
deﬁned as not detecting the same HPV type at two subsequent
visits following an HPV-positive visit, thus requiring ‘two
consecutive visits’.30 The main issue with these deﬁnitions is that
there is no standard biologically relevant duration. While most
studies use ‘two consecutive visits’ for clearance to rule out false-
negatives, this process may also inﬂate the time to clearance since
the exact date of clearance is unknown. It is also possible that
negative HPV diagnostic results could indicate shedding of HPV
virus at quantities below the limit of detection or the latent phase
of HPV. Latency will change the deﬁnition of clearance, persistence,
and reinfection and this concept of HPV is still poorly understood
and further research is warranted.
3.3. HPV testing methods
There are several HPV genotyping methods currently being
used. Molecular methods have been developed for HPV detection,including those based on signal ampliﬁed hybridization, PCR, DNA
sequencing, type-speciﬁc probes, reverse line-blot hybridization,
in situ hybridization, Southern blot hybridization, and immuno-
logical techniques, including ELISA and Western blot. The gold
standard is based on PCR, but still the results can vary across
methods. PCR-based methods are quite sensitive to minimal
amounts of HPV, and even if the virus is not totally cleared from the
system, it is still capable of detecting trace amounts of virus. Yet, it
is not quite possible to characterize and differentiate a new
infection from reinfection with the same HPV type, as some virus
could remain latent in basal cells at undetectable levels.30 Other
parameters of the virus, such as viral variants, viral load,
expression, and genomic integration capacity,30 speciﬁcally in
relation to co-infections, will need to be assessed as possible
markers in future studies.
3.4. Analytical methods
A major analytical challenge has been the prevalent cases and
censoring of events, since, as in any prospective study, it is not clear
how long HPV persists after the end of the study. To account for
some of these, the Cox model has been the standard approach;
however this model cannot simultaneously analyze time to
clearance of several types of HPV because it does not address
possible correlations between incident HPV infections. The Cox
model with the Wei–Lin–Weisfeld (WLW) extension accounts for
the correlation between HPV subtypes within a person and has
population-level interpretations.33 While the Cox model with the
frailty term also accounts for the correlation between HPV
subtypes within a person, it has individual-level interpretations,
which is difﬁcult to comprehend in epidemiological studies.33,34
Other methods, such as the model based on transitional
probability,35 the framework model based on the clustered
longitudinal binary data structure,36 and the discrete-time semi-
Markov models,37 have also been used to account for both
prevalent and incident infections.
Additionally, missing HPV data in longitudinal studies can
have a signiﬁcant impact on correctly identifying persistence
and clearance. Certain assumptions are made based on the data,
but in several instances, a premature censoring or exclusion of
Table 1
HPV clearance and deﬁnitions of prevalence, incidence, clearance, left censoring, and right censoring
P-LC, prevalence, left censored; I, incidence (¥); RC, right censored; C, cleared (*); V1–V5, visits 1 to 5 as examples; M, missing.
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beneﬁt of a larger sample size. For example, if the lower
threshold of assay detection is in question, one would want
HPV-negative results at two consecutive testing intervals, and
the ideal time to clearance will be the midpoint between the last
positive visit and the ﬁrst negative visit (Table 1, scenario 1). In
another example (Table 1, scenario 7), the individual could be
positive for HPV at visit 2, negative at visit 3, data missing at
visit 4, and negative at visit 5. One would assume that the HPV
type remains the same as the previous visit, which indicates that
the HPV virus cleared in this individual and this assumption
holds at visit 5. However, missing data scenarios could be quite
complex and thus, the interpretation could be very subjective.
For consistent use of the intermediate phenotype, a clear
consensus should be made on the biological deﬁnition of HPV
persistence.
4. Conclusions
Throughout this paper we have described how the focus on
cervical cancer and precancerous lesions are too little too late
because the virus has already evaded the immune system and
initiated the integration process. In clinical settings, HPV screening
would be the ﬁrst step, and conﬁrmation of persistent infection
from follow-up HPV testing would complement cytology testing.
While a prophylactic HPV vaccine to four types is available,
challenges remain for researchers to understand the pathogenesis
of HPV, speciﬁcally among those already infected, those who
become infected with other oncogenic types, and those who do not
get vaccinated38. There is consensus that persistence of HPV is the
known, main factor for progression to precancer and cancer. Thus,
research based on the well-deﬁned intermediate phenotype could
provide valuable information for prevention and alternatives to
progression of cancer. The technology to detect the virus is feasible
in most settings and with careful follow-up plans would greatly
assist scientists with their research and clinicians with their
screening programs to help recognize, monitor, and manage the
burden of the disease.Acknowledgements
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